|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
on1410830061 |
| 003 |
OCoLC |
| 005 |
20241006213017.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
231128s2023 sz a o 000 0 eng d |
| 040 |
|
|
|a GW5XE
|b eng
|e rda
|e pn
|c GW5XE
|d OCLCO
|d EBLCP
|d YDX
|d N$T
|d SFB
|d OCLCO
|d UKAHL
|d VLB
|d OCLCO
|
| 019 |
|
|
|a 1410452669
|a 1410593507
|a 1446809377
|
| 020 |
|
|
|a 9783031390050
|q (electronic bk.)
|
| 020 |
|
|
|a 3031390059
|q (electronic bk.)
|
| 020 |
|
|
|z 9783031397721
|
| 020 |
|
|
|z 9783031390043
|
| 020 |
|
|
|z 303139772X
|
| 020 |
|
|
|z 3031390040
|
| 024 |
7 |
|
|a 10.1007/978-3-031-39005-0
|2 doi
|
| 035 |
|
|
|a (OCoLC)1410830061
|z (OCoLC)1410452669
|z (OCoLC)1410593507
|z (OCoLC)1446809377
|
| 050 |
|
4 |
|a RS431.R34
|b R24 2023eb
|
| 072 |
|
7 |
|a PSB
|2 bicssc
|
| 072 |
|
7 |
|a SCI007000
|2 bisacsh
|
| 072 |
|
7 |
|a PSB
|2 thema
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Radiopharmaceutical therapy /
|c Lisa Bodei, Jason S. Lewis, Brian M. Zeglis, editors.
|
| 264 |
|
1 |
|a Cham, Switzerland :
|b Springer,
|c 2023.
|
| 264 |
|
4 |
|c ©2023
|
| 300 |
|
|
|a 1 online resource (xi, 445 pages : illustrations (black and white, and color)).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Part I Fundamentals -- Introduction: The Case for Radiopharmaceutical Therapy -- A Brief History of Radiopharmaceutical Therapy -- The Nuclear Chemistry of Therapeutic Radionuclides -- The Production of Therapeutic Radionuclides -- The Radiobiology of Radiopharmaceutical Therapy: The Input of Imaging and Radiomics -- The Radiopharmaceutical Chemistry of Metallic Radionuclides -- The Radiopharmaceutical Chemistry of the Halogen Radionuclides -- Dosimetry in Radiopharmaceutical Therapy -- Part II Deeper Dives -- Antibodies as Vectors for Radiopharmaceutical Therapy -- Case Study #1: Alpha Particle Therapy of Leukemia Using 225Ac-Lintuzumab -- Case Study #2: Disialoganglioside GD2 as a Target for Radiopharmaceutical Therapy -- Case Study #3: Antibody Fragments in Radiopharmaceutical Therapy -- Peptides as Vectors for Radiopharmaceutical Therapy -- Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapy -- Case Study #5: CXCR4-Targeted Radiotherapeutics -- Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutical Therapy -- Small Molecules as Vectors for Radiopharmaceutical Therapy -- Case Study #7: PSMA-617 -- Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer -- Part III Special Topics -- Auger Electron-Emitting Radionuclides in Radiopharmaceutical Therapy -- Pretargeted Radiopharmaceutical Therapy -- Theranostic Imaging and Radiopharmaceutical Therapy -- The Next Generation of Therapeutic Radionuclides -- Artificial Intelligence and Machine Learning -- The Regulatory Review of Radiotherapeutics: United States of America -- The Regulatory Review of Radiotherapeutics: A European Perspective -- The Regulatory Review of Radiotherapeutics: A Japanese Perspective -- Radiotherapeutics and Nuclear Pharmacy -- Index.
|
| 520 |
|
|
|a This book covers foundational topics in the emerging field of radiopharmaceutical therapy. It is divided into three sections: fundamentals, deeper dives, and special topics. In the first section, the authors examine the field from a birds-eye view, covering topics including the history of radiopharmaceutical therapy, the radiobiology of radiopharmaceutical therapy, and the radiopharmaceutical chemistry of both metallic and non-metallic radionuclides. The second section provides a more in-depth look at specific radiotherapeutics. Chapters include broader discussions of the different platforms for radiopharmaceutical therapy as well as more focused case studies covering individual radiotherapeutics. The third and final section explores a number of areas for further study, including medical physics, artificial intelligence, in vivo pretargeting, theranostic imaging, and the regulatory review process for radiotherapeutics. This book is the first of its kind and is useful for a broad audience of scientists, researchers, physicians, and students across a range of fields, including biochemistry, cancer biology, nuclear medicine, radiology, and radiation oncology.
|
| 588 |
0 |
|
|a Print version record.
|
| 650 |
|
0 |
|a Radiopharmaceuticals
|x Therapeutic use.
|
| 650 |
|
0 |
|a Nuclear medicine.
|
| 650 |
|
0 |
|a Cancer
|x Radiotherapy.
|
| 650 |
|
0 |
|a Radiotherapy.
|
| 650 |
|
0 |
|a Diagnostic imaging.
|
| 650 |
|
0 |
|a Biochemistry.
|
| 650 |
|
7 |
|a biochemistry.
|2 aat
|
| 700 |
1 |
|
|a Bodei, Lisa,
|e editor.
|
| 700 |
1 |
|
|a Lewis, Jason
|q (Jason S.),
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjJf4WVTCQJyxmxJkFbKh3
|
| 700 |
1 |
|
|a Zeglis, Brian Matthew,
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjv4DYtDj6V898RqfH7GVy
|
| 776 |
0 |
8 |
|i Print version:
|t RADIOPHARMACEUTICAL THERAPY.
|d [Place of publication not identified] : SPRINGER INTERNATIONAL PU, 2023
|z 303139772X
|w (OCoLC)1385301718
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://link.springer.com/10.1007/978-3-031-39005-0
|y Click for online access
|
| 903 |
|
|
|a SPRING-ALL2023
|
| 994 |
|
|
|a 92
|b HCD
|